Literature DB >> 21241820

Enhancer of zeste homolog 2: A potential target for tumor therapy.

Yongtao Xiao1.   

Abstract

Enhancer of zeste homolog 2 (EZH2) is a subunit of the Polycomb-Repressive Complex 2 (PRC2), which catalyses the trimethylation of histone H3 on Lys 27 (H3K27) and involves in genes repression. EZH2 is amplified and overexpressed in a variety of cancers, including prostate and breast cancer. Overexpression of EZH2 has been associated with the invasion and progression of malignant cancers, especially with the progression of prostate cancer. Here, we review the structure and biological function of EZH2, especially focused on its activities in the tumorigenesis.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21241820     DOI: 10.1016/j.biocel.2011.01.005

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  13 in total

1.  A key role for EZH2 in epigenetic silencing of HOX genes in mantle cell lymphoma.

Authors:  Meena Kanduri; Birgitta Sander; Stavroula Ntoufa; Nikos Papakonstantinou; Lesley-Ann Sutton; Kostas Stamatopoulos; Chandrasekhar Kanduri; Richard Rosenquist
Journal:  Epigenetics       Date:  2013-10-09       Impact factor: 4.528

2.  Clinicopathological and prognostic significance of EZH2 expression in upper urinary tract carcinoma.

Authors:  Akimasa Hayashi; Teppei Morikawa; Taketo Kawai; Haruki Kume; Shumpei Ishikawa; Yukio Homma; Masashi Fukayama
Journal:  Virchows Arch       Date:  2014-01-21       Impact factor: 4.064

3.  PINK1 regulates histone H3 trimethylation and gene expression by interaction with the polycomb protein EED/WAIT1.

Authors:  Arnaud Berthier; Judit Jiménez-Sáinz; Rafael Pulido
Journal:  Proc Natl Acad Sci U S A       Date:  2013-08-19       Impact factor: 11.205

4.  EZH2 Expression in Naturally Occurring Canine Tumors.

Authors:  Hyun-Ji Choi; Han-Byul Lee; Hyun-Kyu Park; Sung-Min Cho; Hyo-Jeong Han; Sang-Joon Lee; Ji-Young Lee; Su-Jeong Nam; Eun-Ho Cho; Woo-Chan Son
Journal:  Comp Med       Date:  2018-04-02       Impact factor: 0.982

Review 5.  Histone modifications: Targeting head and neck cancer stem cells.

Authors:  John M Le; Cristiane H Squarize; Rogerio M Castilho
Journal:  World J Stem Cells       Date:  2014-11-26       Impact factor: 5.326

6.  Role of EZH2 protein expression in gastric carcinogenesis among Asians: a meta-analysis.

Authors:  Lin Guo; Teng-Fei Yang; Shi-Chao Liang; Ji-Xiang Guo; Qiang Wang
Journal:  Tumour Biol       Date:  2014-04-05

Review 7.  Histone deacetylase inhibitors in glioblastoma: pre-clinical and clinical experience.

Authors:  Pavel Bezecny
Journal:  Med Oncol       Date:  2014-05-18       Impact factor: 3.064

8.  Scalable in situ hybridization on tissue arrays for validation of novel cancer and tissue-specific biomarkers.

Authors:  Sara Kiflemariam; Sandra Andersson; Anna Asplund; Fredrik Pontén; Tobias Sjöblom
Journal:  PLoS One       Date:  2012-03-08       Impact factor: 3.240

9.  Epigenetics in prostate cancer.

Authors:  Costantine Albany; Ajjai S Alva; Ana M Aparicio; Rakesh Singal; Sarvari Yellapragada; Guru Sonpavde; Noah M Hahn
Journal:  Prostate Cancer       Date:  2011-11-30

10.  Dysregulated recruitment of the histone methyltransferase EZH2 to the class II transactivator (CIITA) promoter IV in breast cancer cells.

Authors:  Agnieszka D Truax; Meghna Thakkar; Susanna F Greer
Journal:  PLoS One       Date:  2012-04-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.